Day: September 17, 2024

HORSHAM, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and CEO Dr. Dolev Rafaeli will present a corporate overview at the iAccess Alpha – Buyside Best Ideas Fall Conference 2024. The conference is being held virtually from September 24 – 25, 2024. Presentation Date: September 24, 2024     Time: 12:30 PM ET     Webcast Link: https://www.webcaster4.com/Webcast/Page/3064/51242     Additionally, Dr. Rafaeli and V.P. Finance John Gillings will be available for one-on-one meetings with registered investors of the conference. To register for the conference, and to schedule a meeting,...

A total of 182 samples were collected, seventeen (17) sample locations showed readings greater than 30,000 cps, with six (6) sample locations registering off-scale radioactivity VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) — Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3), is pleased to announce it has completed its extensive summer exploration program on its Nut Lake Project (the “Nut Lake Project” or the “Project”) located in the Thelon Basin in Nunavut. The Project covers approximately 5,853 hectares near the Northern Tip of the Yathkyed Basin, a sub-basin of the Thelon Basin (please see Figure 1). Figure 1: Nut Lake Project claim map 2024 Work Program On behalf of Greenridge, Dahrouge Geological Consulting Ltd. (“DGC” or “Dahrouge”) conducted an eighteen-day, large-scale exploration...

Mark Van Genderen Promoted to Chief Operating OfficerChief Human Resources Officer Linda Evans to Retire at Year-EndShannan Vlieger Promoted to Senior Vice President, People and Culture MILWAUKEE, Sept. 17, 2024 (GLOBE NEWSWIRE) — Douglas Dynamics, Inc. (NYSE: PLOW), North America’s premier manufacturer and upfitter of work truck attachments and equipment, today announced several senior management team changes. Mark Van Genderen has been appointed as Chief Operating Officer (COO) of Douglas Dynamics, and President of Work Truck Attachments, effective immediately. Chief Human Resources Officer, Linda Evans, has announced her intent to retire on January 2, 2025, and Shannan Vlieger has been named Senior Vice President, People and Culture, effective October 1, 2024. Mark Van Genderen Appointed Chief Operating Officer and President...

In the last week, Beamr participated in two top global events: Oracle CloudWorld 2024 and IBC 2024 Herzliya, Israel, Sept. 17, 2024 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video optimization and modernization technology and solutions, is pleased to share recent updates from the past week regarding its participation in top global events, where it held demonstrations of innovative technologies and key meetings with video industry leaders and businesses from around the globe. The events include Oracle CloudWorld 2024, held in Las Vegas, from September 9-12, 2024, and IBC 2024, held in Amsterdam, the Netherlands, from September 13-16, 2024. “Beamr participated in two major conferences, Oracle CloudWorld and IBC, holding dozens of meetings with leading media and entertainment companies”, said Beamr CEO, Sharon...

Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a monotherapy and in combination with standard of care agents in preclinical models of HCC Proof-of-concept data for OTX-2002 support potential of epigenomic controllers to effectively target and modulate expression of nearly any human gene, including historically undruggable targets Data further validate the OMEGA platform’s potential to rapidly and prospectively design, develop and advance programmable epigenomic mRNA medicines for the treatment of a broad range of diseases CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA...

WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA’s decision was based on a complete response submitted by the Company. “We are pleased with the resolution of the partial clinical hold – a decision that was supported by non-clinical and clinical data from our ongoing Phase 1 trial,” said Petra Kaufmann, M.D., F.A.A.N., Chief Medical Officer at Vigil. “While the partial clinical hold did not delay clinical development of VG-3927, the option to increase the exposure limit provides us the best opportunity...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption Launch expected early in the fourth quarter of 2024 GERMANTOWN, Md. and PARSIPPANY, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the next-generation Eversense® 365 CGM system for people with Type 1 and Type 2 diabetes aged 18 years...

Asset acquisition of Cook Medical’s end-to-end lead management product portfolio strengthens Merit’s existing electrophysiology and CRM business Asset acquisition projected to add approximately $40 million of revenue, on an annualized basis beginning in fiscal year 2025, with a solid growth profile serving an underpenetrated global lead management market Merit reaffirms full-year 2024 financial guidance previously issued on August 1, 2024, and updates full-year 2024 financial guidance to include the projected impact from this acquisition post-close SOUTH JORDAN, Utah, Sept. 17, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced it has signed a definitive asset purchase agreement to purchase Cook Medical’s lead management portfolio for total cash consideration...